ArticleSkeletal radiology2019
Imaging features of phosphaturic mesenchymal tumors.
Article in Skeletal radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MRI findings for differentiating benign and malignant soft tissue tumors: a systematic review-part 2: key imaging findings.Skeletal radiology · 2026Pooled it
- Article
- Spinal phosphaturic mesenchymal tumor: a case report of thoracic vertebral involvement with preoperative embolization and literature review.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Imaging findings in the head and neck of phosphaturic mesenchymal tumors.Neuroradiology · 2026Article
- Soft tissue reporting and data system (soft tissue-RADS): framework for radiologists specializing in imaging of musculoskeletal tumors and tumor-like lesions.Skeletal radiology · 2026Review
- Clinical and imaging characteristics of phosphaturic mesenchymal tumors: a case series analysis.BMC cancer · 2026Article
- Expanding the differential diagnosis of bone-forming tumors: a new entity characterized by a NIPBL::BEND2 fusion.Skeletal radiology · 2026Article
- Article
- Serum Phosphorus Is a Fast and Highly Sensitive Marker Predictive of a Complete Cure of Tumor-Induced Osteomalacia.Journal of clinical medicine · 2025Article
- Surgical treatment as a key determinant of outcome in phosphaturic mesenchymal tumors of the bone and soft tissue: a systematic review and case series.EFORT open reviews · 2025Article
- Clinical features and treatment of hypophosphatemia and associated complications induced by Phosphaturic mesenchymal tumors: A case series of six patients.Bone reports · 2025Article
- Case Report: Phosphaturic mesenchymal tumor presenting solely as knee pain without hypophosphatemia.Frontiers in oncology · 2025Article
- Phosphaturic mesenchymal tumor: management and outcomes of ten patients treated at a single institution.Skeletal radiology · 2024Article
- Spinal phosphaturic mesenchymal tumors: a rare etiology causing tumor-induced osteomalacia-a review of experience at a UK tertiary referral center and literature review.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2024Review
- Prolonged generalized osteomalacia associated with a sinonasal cavity phosphaturic mesenchymal tumor: A case report.Clinical case reports · 2024Article
- Advanced tumour-induced osteomalacia secondary to sinonasal phosphaturic mesenchymal tumour.SA journal of radiology · 2024Article
- Phosphaturic Mesenchymal Tumors with or without Phosphate Metabolism Derangements.Current oncology (Toronto, Ont.) · 2023Review
- Unusual phosphaturic mesenchymal tumor mimicking osteoid osteoma.Radiology case reports · 2023Article
- Tumor-induced Osteomalacia Secondary to Phosphaturic Mesenchymal Tumor.Radiology. Imaging cancer · 2023Article
- Phosphaturic Mesenchymal Tumors: Rethinking the Clinical Diagnosis and Surgical Treatment.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the CT and MR imaging features of phosphaturic mesenchymal tumors (PMTs). MATERIALS AND
methodsWith IRB approval, our institutional radiology/pathology database was reviewed for pathologically-proven PMTs. CT and MRI examinations were reviewed in consensus noting several imaging features, and if available, comparative molecular imaging tests were analyzed.
resultsWe identified 39 patients (21 male, 18 females) with 40 PMTs [mean age, 52.9 ± 14.9 years (range, 14-78)], including 20 bone and 20 soft tissue lesions. Mean maximal lesion diameter was 3.4 ± 2.0 cm (range, 1.1-9.8). 12/18 primary bone lesions (66.6%) were osteolytic and 15/20 (75.0%) had a narrow zone of transition. Internal matrix was present in 18/32 (56.3%) lesions. PMTs were most commonly T1 isointense (31/37, 83.8%), T2 hyperintense (14/36, 38.9%), and solidly enhancing (21/30, 70.0%). The majority (32/36, 88.9%) contained areas of dark T2 signal. 8/9 PMTs were positive by
conclusionsOsseous PMTs are commonly osteolytic with a narrow zone of transition. Both bone and soft tissue PMTs often contain matrix and areas of dark T2 signal on MRI, independent of the presence of matrix. However, PMTs may mimic other bone and soft tissue neoplasms, including fibrous dysplasia, tenosynovial giant cell tumor, and even atypical lipomatous tumor. As such, clinical presentation and laboratory correlation are critical to PMT recognition and accurate diagnosis.
Indexed as
Identifiers
29987349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.